Between 2008 and 2016, five patients with AML with mutated FLT3 received TKI treatment in our hospital and, after a few months, three of them developed resistance (patients #1, #2, and #3, see Table 1). This evidence concerns the gene FLT3 and acute myeloid leukemia.